https://orcid.org/0000-0001-7919-9099
References
- Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51(1):1–17. doi:10.1016/j.survophthal.2005.11.007.
- Mack HG, Symons RCA, de Jong G. Bull’s eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Am J Ophthalmol Case Reports [Internet]. 2017 Oct 4;9:1–6. 10.1016/j.ajoc.2017.10.006
- Tomatsu S, Pitz S, Hampel U. Ophthalmological findings in mucopolysaccharidoses. J Clin Med. 2019 Sep;8(9):1467. doi:10.3390/jcm8091467.
- Usui T, Shirakashi M, Takagi M, Abe H, Iwata K. Macular edema-like change and pseudopapilledema in a case of Scheie syndrome. J Clin Neuroophthalmol. 1991 Sep;11(3):183–85.
- Huang C-T, Chu S-Y, Lee Y-C. Optical coherence tomography of chorioretinopathy caused by mucopolysaccharidoses. Ophthalmology. 2015 Jul;122(7):1535–37. doi:10.1016/j.ophtha.2015.01.015.
- Seok S, Lyu IJ, Park KA, Oh SY. Spectral domain optical coherence tomography imaging of mucopolysaccharidoses I, II, and VI A. Graefe’s Arch Clin Exp Ophthalmol = Albr von Graefes Arch fur Klin und Exp Ophthalmol. 2015 Dec;253(12):2111–19. doi:10.1007/s00417-015-2953-y.
- Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, Wesley J, McIvor RS, et al. Mucopolysaccharidosis type I: a review of the natural history and molecular pathology. Cells. 2020 Aug;9(8):1838. doi:10.3390/cells9081838.
- Pereira VG, Gazarini ML, Rodrigues LC, da Silva FH, Han SW, Martins AM, Tersariol ILS, D’Almeida V, et al. Evidence of lysosomal membrane permeabilization in mucopolysaccharidosis type I: rupture of calcium and proton homeostasis. J Cell Physiol. 2010 May;223(2):335–42. doi:10.1002/jcp.22039.
- Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147–54. doi:10.2147/OPTH.S4684.